Avila

Covalent small molecule drug discovery platform

Avila developed a novel chemistry approach ‘Avilomics’ to discover oral small molecule covalent inhibitors of proteases and kinases. Avilomics allows the design of highly specific compounds that irreversibly bind to the protein target to improve therapeutic index and clinical efficacy.

Avila’s most advanced product candidate, AVL-292, a highly selective Btk inhibitor was in Phase I clinical development at the time of its acquisition by Celgene.

CEO  Katrine Bosley

Advent Contact  Raj Parekh

Advent invested in the Series A in 2007. Avila was acquired by Celgene in 2012 for $925m in cash and milestones.
Exited Investments
26 January 2012 in Avila, Press Release

Celgene to Acquire Avila Therapeutics

Press Release.   Oral Btk inhibitor AVL-292 offers promising potential for treatment of B-cell diseases Avilomics™ Platform enhances drug discovery capabilities SUMMIT, NJ and BEDFORD, MA – January 26, 2012…
Read More
20 January 2012 in Avila, Press Release

Avila Announces FDA Allowance of Partner Clovis Oncology’s IND Application

Press Release.   Avila Announces FDA Allowance of Partner Clovis Oncology’s IND Application for CO-1686, an Oral EGFR Mutant-Selective Inhibitor Triggers $4 Million Milestone Payment to Avila BEDFORD, Mass.--(BUSINESS WIRE)--…
Read More
8 June 2011 in Avila, Press Release

Avila Therapeutics agreement with NIAID

Press Release.   WALTHAM, MA – June 8, 2011 –Avila Therapeutics, Inc. a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced that it has entered…
Read More
2 November 2010 in Avila, Press Release

Avila Presents New Data on its Novel, Orally-Available Targeted Covalent Drug, AVL-192

Press Release.   Covalent Inhibition Achieves Superior Potency Against Drug-Resistant HCV Mutants   BOSTON and WALTHAM, MA – Avila Therapeutics™, Inc., a biotechnology company developing novel targeted covalent drugs, presented…
Read More
4 October 2010 in Avila, Press Release

Avila Initiates Phase 1 Clinical Study of AVL-292, a Targeted Covalent Drug and Novel Potential Treatment for B Cell Cancers and Autoimmune Diseases

Press Release.   WALTHAM, Mass. - Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the…
Read More
30 March 2010 in Avila, Press Release

The Leukemia & Lymphoma Society and Avila Therapeutics Enter Partnership to Accelerate Development of AVL-292 For Patients with Cell B Malignancies

Press Release.   White Plains, NY and Waltham, Mass. - The Leukemia & Lymphoma Society (LLS) and Avila Therapeutics, Inc., today announced they have established a collaboration to support development…
Read More
3 November 2009 in Avila, Press Release

Avila presents data on its novel, orally-available protease inhibitor, AVL-181, demonstrating viral clearance of hepatitis C virus in preclinical models

Press Release.   BOSTON & WALTHAM, Mass. - Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on…
Read More
27 July 2009 in Avila, Press Release

Avila Therapeutics Announces Agreement with Novartis to Develop Novel Covalent Drug Candidate

Press Release.   WALTHAM, Mass.--(BUSINESS WIRE)-- Avila Therapeutics, Inc., an emerging biotechnology company, announced today that it has entered into an option agreement with the Novartis Option Fund focused on…
Read More
27 July 2009 in Avila, Press Release

Avila Therapeutics, Inc. Closes $30 Million Series B Financing

Press Release.   Company to Advance Novel Class of Protein-Silencing Covalent Drugs into Clinic Development   WALTHAM, Mass.--(BUSINESS WIRE)-- Avila Therapeutics, Inc., an emerging biotechnology company, announced today that it…
Read More
15 May 2009 in Avila, Press Release

Avila Therapeutics Appoints Katrine S. Bosley as Company’s First CEO

Press Release.   WALTHAM, Mass.--(BUSINESS WIRE)-- Avila Therapeutics, an emerging biopharmaceutical company developing a revolutionary new class of medicines known as covalent drugs, announced today that Katrine S. Bosley has…
Read More
5 January 2009 in Avila, Press Release

Avila Therapeutics May Have Found Achilles™ Heel of Hepatitis C Virus

Press Release.   Avila Therapeutics emerged from stealth mode in December and told Xconomy about its secret sauce to systematically create permanent, covalent bonds with protein disease targets. Now the…
Read More